SG Americas Securities LLC Acquires 56,982 Shares of Moderna, Inc. (NASDAQ:MRNA)

SG Americas Securities LLC boosted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 108.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 109,761 shares of the company’s stock after purchasing an additional 56,982 shares during the period. SG Americas Securities LLC’s holdings in Moderna were worth $4,564,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. MassMutual Private Wealth & Trust FSB boosted its position in shares of Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the period. Blue Trust Inc. boosted its stake in shares of Moderna by 365.6% in the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after acquiring an additional 574 shares during the period. Larson Financial Group LLC grew its position in shares of Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after purchasing an additional 317 shares in the last quarter. Rakuten Securities Inc. raised its stake in Moderna by 477.3% during the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock valued at $63,000 after purchasing an additional 778 shares during the period. Finally, Brooklyn Investment Group bought a new position in Moderna in the 3rd quarter worth approximately $80,000. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Down 2.3 %

Shares of MRNA opened at $41.41 on Friday. The stock’s 50-day moving average price is $40.60 and its 200-day moving average price is $64.04. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $15.94 billion, a price-to-earnings ratio of -7.12 and a beta of 1.60. Moderna, Inc. has a 52 week low of $31.94 and a 52 week high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm’s revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the business earned ($1.39) earnings per share. On average, sell-side analysts predict that Moderna, Inc. will post -9.27 EPS for the current year.

Analysts Set New Price Targets

MRNA has been the subject of several research reports. Piper Sandler reissued an “overweight” rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a report on Monday, November 18th. Wolfe Research began coverage on shares of Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 target price for the company. Jefferies Financial Group reduced their price target on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research report on Tuesday, October 15th. Hsbc Global Res raised shares of Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 26th. Four equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $75.58.

Insiders Place Their Bets

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 in the last 90 days. 15.70% of the stock is owned by insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.